Edgewise rated as a new Hold at Stifel on a balanced risk-reward setup
Source: SeekingAlpha
2025-01-22 09:56:20 ET
More on Edgewise Therapeutics
- Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data
- Edgewise rises on mid-stage trial results for muscular dystrophy candidate
- Vertex leads J.P. Morgan's top biotech picks list for 2025
- Seeking Alpha’s Quant Rating on Edgewise Therapeutics
- Historical earnings data for Edgewise Therapeutics
Read the full article on Seeking Alpha
For further details see:
Edgewise rated as a new Hold at Stifel on a balanced risk-reward setup
Edgewise Therapeutics Inc.
NASDAQ: EWTX
EWTX Trading
-3.01% G/L:
$37.88 Last:
819,118 Volume:
$40 Open:
EWTX Latest News
June 01, 2026 08:30:00 am
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
EWTX Stock Data
$3,280,862,770
54,628,112
N/A
52
N/A
Biotechnology & Life Sciences
Healthcare
US
Boulder
